Autonomix Medical Files 8-K on Agreements and Equity Sales

TL;DR

Autonomix Medical (AMIX) filed an 8-K detailing material agreements and equity sales. Keep an eye on this.

AI Summary

Autonomix Medical, Inc. filed an 8-K on August 25, 2025, reporting on a material definitive agreement, unregistered sales of equity securities, and financial statements. The company, incorporated in Delaware with its principal executive offices in The Woodlands, TX, operates in the surgical and medical instruments sector.

Why It Matters

This filing provides crucial updates on Autonomix Medical's material agreements and equity transactions, which could impact its financial standing and future operations.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can indicate significant corporate actions or financing events that carry inherent risks.

Key Numbers

• 001-41940 — SEC File Number (Identifies the company's filing history with the SEC.)
• 47-1607810 — EIN (Employer Identification Number for tax purposes.)

Key Players & Entities

• Autonomix Medical, Inc. (company) — Registrant
• August 25, 2025 (date) — Date of earliest event reported
• The Woodlands, TX (location) — Principal executive offices location
• 3841 (industry_code) — Standard Industrial Classification for Surgical & Medical Instruments & Apparatus

FAQ

Key Financial Figures

• $0.001 — h Registered Common Stock , par value $0.001 per share AMIX The Nasdaq Stock Mark
• $15.0 million — incoln Park committed to purchase up to $15.0 million in shares of the Company's common stock
• $500,000 — ingle Regular Purchase shall not exceed $500,000. The purchase price per share for each
• $1.3351 — he Purchase Agreement equals or exceeds $1.3351 per share (which represents the lower o

Filing Documents

• amix20250825_8k.htm (8-K) — 39KB
• ex_856934.htm (EX-10.1) — 272KB
• ex_856935.htm (EX-10.2) — 87KB
• image1.jpg (GRAPHIC) — 2KB
• 0001437749-25-027719.txt ( ) — 622KB
• amix-20250825.xsd (EX-101.SCH) — 3KB
• amix-20250825_def.xml (EX-101.DEF) — 12KB
• amix-20250825_lab.xml (EX-101.LAB) — 15KB
• amix-20250825_pre.xml (EX-101.PRE) — 12KB
• amix20250825_8k_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On August 25, 2025, Autonomix Medical, Inc. (the "Company") entered into a purchase agreement, dated as of August 25, 2025 (the "Purchase Agreement"), with Lincoln Park Capital Fund, LLC ("Lincoln Park"), pursuant to which Lincoln Park committed to purchase up to $15.0 million in shares of the Company's common stock, $0.001 par value per share (the "Common Stock"), subject to satisfaction of the conditions and certain limitations contained in the Purchase Agreement. Concurrently with the execution of the Purchase Agreement on August 25, 2025, the Company also entered into a registration rights agreement, dated as of August 25, 2025 (the "Registration Rights Agreement"), with Lincoln Park, relating to the registration under the Securities Act of 1933, as amended (the "Securities Act"), of the offer and sale of the securities that have been and may be issued and sold by the Company to Lincoln Park, from time to time in the Company's sole discretion, from and after the Commencement Date (defined below), under the Purchase Agreement and to take such other specified actions to maintain such registration under the Securities Act. Upon the terms and subject to the conditions set forth in the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase, up to $15.0 million in shares of Common Stock. Such sales of Common Stock, if any, will be subject to certain limitations set forth in the Purchase Agreement, and may occur from time to time, at the Company's sole discretion, over a period of up to 24 months, commencing on the date that each of the conditions to Lincoln Park's purchase obligations set forth in the Purchase Agreement have been initially satisfied (the date on which all such conditions are initially satisfied, the "Commencement Date"), including that a registration statement covering the resale by Lincoln Park of shares of Comm

02. Unregistered Sales of Equity Securities

Item 3.02. Unregistered Sales of Equity Securities The information contained in Item 1.01 is hereby incorporated by reference into this Item 3.02. In the Purchase Agreement, Lincoln Park represented to the Company, among other things, that it is an "accredited investor" (as such term is defined in Rule 501(a)(3) of Regulation D under the Securities Act of 1933. The Commitment Shares were issued and the Purchase Shares will be issued and sold by the Company to Lincoln Park in reliance upon the exemptions from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D thereunder.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. No. Description 10.1 Purchase Agreement, dated August 25, 2025, by and between the Company and Lincoln Park Capital Fund, LLC.* 10.2 Registration Rights Agreement, dated August 25, 2025, by and between the Company and Lincoln Park Capital Fund, LLC. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Annexes, schedules and/or exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby agrees to furnish supplementally a copy of any omitted attachment to the SEC on a confidential basis upon request. Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AUTONOMIX MEDICAL, INC. By: /s/ Trent Smith Trent Smith Chief Financial Officer Dated: August 26, 2025

View Full Filing

View this 8-K filing on SEC EDGAR